NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company focused on natural killer (NK) cell immunotherapies, targeting oncology and neurodegenerative diseases. The company went public through a merger with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Acquisition LLC that completed its IPO in 2021. NKGen filed its 10-Q quarterly report with the SEC on August 15, 2022, accession number 0001410578-22-002592, reflecting its status as a newly public company operating in the cell therapy sector. NKGen's lead programs center on proprietary NK cell platforms designed for both allogeneic and autologous treatment approaches. For full filing history, ownership data, and deal analytics on NKGN and hundreds of other SPAC-derived companies, sign up for SpacDesk at spacdesk.com.